The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | Community-based mass screening with low-dose CT for lung cancer in Guangzhou
Sanjay Popat, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, provides an overview of a study (NCT04938804) investigating community-based mass screening with low-dose CT (LDCT) for lung cancer in Guangzhou which aimed to investigate an approach for lung cancer screening in the general population and develop a risk prediction model to improve risk assessment. A total of 11,708 participants were screened. 189 (1.6%) lung cancers were diagnosed, among which 162 (85.7%) cases were in stage 0-I. The study demonstrated that early-stage lung cancer can be identified with a single LDCT screen in in Guangzhou and markedly improves survival. Additionally, a risk prediction model based on participant characteristics combined with CEA was shown to improve lung cancer risk assessment, identifying those most likely to benefit from screening. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
